Accessibility

Accessibility Statement

NAROVAC is committed to ensuring digital accessibility for all users.

Our commitment

NAROVAC is committed to making its website accessible to the widest possible audience, including individuals with visual, hearing, motor or cognitive impairments. We strive to meet the Web Content Accessibility Guidelines (WCAG) 2.1 AA standards.

Accessibility features

This website incorporates the following accessibility features:

  • Clear, consistent page structure and navigation
  • Text content written in plain language where possible
  • Sufficient colour contrast between text and background
  • Images include descriptive alt text
  • Links are identifiable and descriptive
  • Content is responsive and readable on various screen sizes
  • Keyboard-navigable interface elements

Ongoing improvements

We recognise that accessibility is an ongoing effort. We regularly review the website and make improvements to ensure it remains accessible as technologies and standards evolve.

Feedback

If you encounter any accessibility barriers on this website, or if you have suggestions for improvement, please contact us at info@narovac.com. We aim to respond to accessibility feedback within five working days.

Last updated: July 2026

Pharmacovigilance Notice

Report all suspected Adverse Drug Reactions (ADRs) and Adverse Events Following Immunization (AEFIs):

039 3104369 / 0800 111 811
Report an ADR/AEFI